Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering-Plough consolidates operations

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough will begin "phasing out" manufacturing operations at its Manati, Puerto Rico site, with complete closure anticipated by the end of the year, the pharmaceutical firm announces June 1. The company also anticipates workforce reductions at its facilities located in Las Piedras, Puerto Rico and New Jersey. The facilities consolidation will affect a total of approximately 1,100 positions, mostly in 2006, and is part of an effort to "streamline its global supply chain and further enhance the company's long-term competitiveness," the firm states. Schering-Plough expects $235 mil. to $260 mil. in charges associated with severance pay, fixed asset and inventory write-offs, and accelerated depreciation and closure costs, about half of which will be incurred in the second quarter of 2006. "The remaining expenses are expected to be recorded in the second half of 2006 as incurred," the firm says. Products affected by the closing of the Manati facility include Afrin (oxymetazoline HCl) nasal spray. Manufacturing operations for the topical sinus spray will be relocated to the Cleveland, Tenn. facility, according to Schering-Plough...

You may also be interested in...

Sales & Earnings In Brief

GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...

Schering-Plough’s new trial model

A new global model for clinical trial operations will be adopted by Schering-Plough to improve the planning and management of the progression of therapeutic compounds during the clinical trial process. The Global Clinical Harmonization program is "designed to maximize its product portfolio through centralized global processes and function units that are efficient, compliant and customer-focused," the company states in a release June 6. The Global Clinical Operations will establish a "global set of standards, policies and practices, and build a management system that will oversee clinical trials worldwide," the firm explains. All trials will be held to these standards regardless of trial type, phase or geography. The adoption of the new model marks another step in Schering-Plough's Action Agenda to build the firm into a "high-performance competitor for the long term," according to Chairman and CEO Fred Hassan. The firm recently began a consolidation of its operating facilities which will affect approximately 1,100 positions and close the Manati, Puerto Rico manufacturing site (1"The Tan Sheet" June 5, 2006, In Brief)...

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts